How worried should we be about bird flu? Why is the nascent radiopharmaceuticals field struggling to find qualified workers? And which obesity drug is the best?
We talk about all that and more on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. You might not be paying attention, or maybe you just hope it goes away. We’re referring to the serious bird flu outbreak that started a bit more than 8 months ago. Well, bird flu is still here and the number of reported cases in people is growing. STAT’s infectious disease reporter Helen Branswell joins us for an update.
But first, we’ll break down the results from a GLP-1 showdown study that compared Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy. Allison DeAngelis will share her recent reporting on a talent shortage that is posing new challenges to the fast-growing radiopharmaceutical industry.
For more on bird flu, look here and here. Allison’s radiopharmaceuticals story can be read here. And a story on Zepbound vs. Wegovy is here.
Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.